Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Durvalumab + Tremelimumab & Hepatocellular Carcinoma (HCC), the FDA approved Durvalumab + Tremelimumab on 21 Oct 2022 for adult patients with unresectable hepatocellular carcinoma, based on HIMALAYA (NCT03298451) (1). The regimen is the STRIDE schedule (single 300 mg priming dose of tremelimumab plus durvalumab 1500 mg q4w, then durvalumab maintenance), showing OS benefit vs sorafenib (1, 2)
The CHMP adopted a positive opinion in Dec 2022 recommending a new indication for Imjudo + Imfinzi for first‑line treatment of adults with advanced or unresectable HCC. The European …